[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc (GSK.LN)

Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 80,232,075
  • Shares Outstanding, K 4,005,595
  • Annual Sales, $ 32,667 M
  • Annual Income, $ 5,716 M
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales 2.51
  • Price/Cash Flow 10.62
  • Price/Book 4.49
  • Price/Earnings ttm 14.10
  • Earnings Per Share ttm 1.42
  • Most Recent Earnings $0.43 on 04/29/26
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) 0.68 (3.39%)
  • Most Recent Dividend 0.170 on 05/14/26
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,839.000 +7.64%
on 06/09/26
2,049.000 -3.39%
on 07/06/26
+63.000 (+3.29%)
since 06/08/26
3-Month
1,690.000 +17.13%
on 05/19/26
2,202.000 -10.10%
on 04/15/26
-145.500 (-6.85%)
since 04/08/26
52-Week
1,288.605 +53.62%
on 08/21/25
2,282.000 -13.26%
on 02/18/26
+565.500 (+39.99%)
since 07/08/25

Most Recent Stories

More News
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment 1 ...

SPRO : 2.15 (-0.46%)
GSK.LN : 1,979.500 (-1.17%)
GSK : 52.74 (-1.09%)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs...

SPRO : 2.15 (-0.46%)
GSK.LN : 1,979.500 (-1.17%)
GSK : 52.74 (-1.09%)
Stocks Set to Extend Rebound Amid AI Dip-Buying

June S&P 500 E-Mini futures (ESM26) are up +0.46%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.69% this morning as a rebound in the AI trade entered a second day.

META : 605.49 (-1.64%)
GOOGL : 360.91 (-1.67%)
FCEL : 23.17 (-10.75%)
MTN : 142.60 (-0.39%)
MU : 944.50 (+0.65%)
GSK.LN : 1,979.500 (-1.17%)
ESM26 : 7,508.43s (+1.13%)
CIEN : 438.19 (+4.60%)
UBSG.Z.IX : 41.150 (-1.34%)
INTC : 108.04 (-2.13%)
APLD : 30.69 (-0.07%)
NQM26 : 30,263.35s (+1.94%)
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

On-screen parenting duo stars in new, original video highlighting relatable parenting moments, educating viewers about meningococcal disease, also known as meningitis GSK’s Ask2BSure...

GSK.LN : 1,979.500 (-1.17%)
GSK : 52.74 (-1.09%)
Stock Index Futures Gain on Tech Boost Ahead of Fed Decision and Megacap Earnings

June S&P 500 E-Mini futures (ESM26) are up +0.14%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.27% this morning, buoyed by gains in technology stocks, while investors await the Federal Reserve’s...

GOOGL : 360.91 (-1.67%)
ADS.D.DX : 179.875 (-4.14%)
BE : 244.14 (-9.43%)
SNDK : 1,670.00 (+3.23%)
F : 13.51 (-0.37%)
ESM26 : 7,508.43s (+1.13%)
MSFT : 383.47 (-1.38%)
QCOM : 186.49 (+1.92%)
STX : 841.21 (+1.64%)
V : 346.90 (-1.50%)
WDC : 541.00 (+1.67%)
AZN.LN : 14,240.000 (-0.86%)
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 *

GSK.LN : 1,979.500 (-1.17%)
GSK : 52.74 (-1.09%)
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir ...

GSK.LN : 1,979.500 (-1.17%)
PFE : 24.19 (+0.50%)
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas

BORAY : 2.5900 (+15.11%)
GSK.LN : 1,979.500 (-1.17%)
GSK : 52.74 (-1.09%)
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse cardiovascular events* in adults...

GSK.LN : 1,979.500 (-1.17%)
GSK : 52.74 (-1.09%)
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...

GSK.LN : 1,979.500 (-1.17%)
GSK : 52.74 (-1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 2,077.667
2nd Resistance Point 2,054.333
1st Resistance Point 2,028.667
Last Price 1,979.500
1st Support Level 1,979.667
2nd Support Level 1,956.333
3rd Support Level 1,930.667

See More

52-Week High 2,282.000
Last Price 1,979.500
Fibonacci 61.8% 1,902.523
Fibonacci 50% 1,785.302
Fibonacci 38.2% 1,668.082
52-Week Low 1,288.605

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.